Article
Hematology
Zhenhua Li, Ti-Cheng Chang, Jacob J. Junco, Meenakshi Devidas, Yizhen Li, Wenjian Yang, Xin Huang, Dale J. Hedges, Zhongshan Cheng, Mary Shago, Andrew J. Carroll, Nyla A. Heerema, Julie Gastier-Foster, Brent L. Wood, Michael J. Borowitz, Lauren Sanclemente, Elizabeth A. Raetz, Stephen P. Hunger, Eleanor Feingold, Tracie C. Rosser, Stephanie L. Sherman, Mignon L. Loh, Charles G. Mullighan, Jiyang Yu, Gang Wu, Philip J. Lupo, Karen R. Rabin, Jun J. Yang
Summary: This study investigates the genomics of Down syndrome-related acute lymphoblastic leukemia (DS-ALL) and identifies 15 molecular subtypes, as well as abnormal activation of key genes. It also reveals the common occurrence of somatic genomic abnormalities mediated by gene rearrangements in DS-ALL and the association between subtype heterogeneity and prognosis. These findings provide important insights into the biology of DS-ALL and offer opportunities for individualized treatment.
Article
Cell Biology
Elena Mariotto, Diana Corallo, Marcella Pantile, Emanuela Giarin, Martina Pigazzi, Giuseppe Basso, Giampietro Viola, Sanja Aveic
Summary: BAG1 is deregulated in B-ALL, with levels decreasing during disease remission but drastically increasing at relapse. Depletion of BAG1 induces apoptosis and cell cycle arrest, while also increasing sensitivity to chemotherapy agents. Inhibitors of BAG1 show cytotoxic effects on B-ALL cells and synergize with pan-BCL inhibitors.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Review
Health Care Sciences & Services
Ross Salvaris, Pasquale Luke Fedele
Summary: In the past decade, significant progress has been made in understanding the genetic mutations underlying acute lymphoblastic leukemia (ALL), leading to the discovery of driver mutations with prognostic implications. Targeted therapies and immunotherapies have shown promise in treating different subtypes of ALL, but come with unique toxicities and sequencing considerations. Advances in T-ALL have been slower compared to B-ALL, but promising results have been seen with agents targeting T cell antigens like nelarabine and CAR T cell therapy.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Hye Won Kook, Jin Ju Kim, Mi Ri Park, Ji Eun Jang, Yoo Hong Min, Seung-Tae Lee, Saeam Shin, June-Won Cheong
Summary: This study compared the clinicopathological characteristics and outcomes of patients with therapy-related acute lymphoblastic leukemia (tr-ALL) and de novo ALL (dn-ALL). The results showed some differences in gene mutations, but no significant differences were found in overall survival and progression-free survival between the two groups.
Article
Oncology
Ioannis Peppas, Anthony M. Ford, Caroline L. Furness, Mel F. Greaves
Summary: Children with newly diagnosed acute lymphoblastic leukaemia may have a delayed maturation of the gut microbiome compared with healthy children, which could be associated with early-life epidemiological factors and contribute to the risk of transformation of preleukaemic clones in response to common infectious triggers.
NATURE REVIEWS CANCER
(2023)
Article
Oncology
Angela Gutierrez-Camino, Chantal Richer, Manon Ouimet, Claire Fuchs, Sylvie Langlois, Fida Khater, Maxime Caron, Patrick Beaulieu, Pascal St-Onge, Alain R. Bataille, Daniel Sinnett
Summary: This study conducted comprehensive genomic and transcriptomic analysis of FLT3 in 342 childhood ALL patients, and identified FLT3 mutations and their clinical implications. The study also discovered a novel FLT3 mutation and its impact on treatment response. Furthermore, FLT3 alterations were found to be associated with specific ALL subgroups.
BRITISH JOURNAL OF CANCER
(2023)
Article
Hematology
Andrea Biondi, Valentino Conter, Mammen Chandy, Primus Ewald, Marie Lucia de Martino Lee, Vivek S. Radhakrishnan, Wannaphorn Rotchanapanya, Patricia Scanlan, Owen Patrick Smith, Boubacar Togo, Peter Hokland
Summary: As hematologists, the best treatment for patients with blood diseases may vary due to differing opinions and constraints, as well as differences in patient presentation and understanding worldwide. Patients in developed countries often present early and have a better understanding of their disease, impacting treatment management and outcomes.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Theodore W. Laetsch, Shannon L. Maude, Adriana Balduzzi, Susana Rives, Henrique Bittencourt, Michael W. Boyer, Jochen Buechner, Barbara De Moerloose, Muna Qayed, Christine L. Phillips, Michael A. Pulsipher, Hidefumi Hiramatsu, Ranjan Tiwari, Stephan A. Grupp
Summary: This study evaluated the efficacy and side effects of tisagenlecleucel in DS-ALL patients and compared it with patients without DS. The results showed that tisagenlecleucel had similar remission rates and safety profiles in DS-ALL patients as in patients without DS.
Article
Multidisciplinary Sciences
Eleanor L. Woodward, Minjun Yang, Larissa H. Moura-Castro, Hilda van den Bos, Rebeqa Gunnarsson, Linda Olsson-Arvidsson, Diana C. J. Spierings, Anders Castor, Nicolas Duployez, Marketa Zaliova, Jan Zuna, Bertil Johansson, Floris Foijer, Kajsa Paulsson
Summary: This study reveals that the aneuploidies in high hyperdiploid acute lymphoblastic leukemia (HeH ALL) may originate early and follow a punctuated evolution process, using single-cell whole genome sequencing and in silico modeling.
NATURE COMMUNICATIONS
(2023)
Review
Oncology
Chun-fung Sin, Pui-hei Marcus Man
Summary: Acute lymphoblastic leukaemia (ALL) has a better prognosis in pediatric patients but a poorer outcome and higher relapse rate in adults. Proteasome inhibitors, as a new type of drug, have shown promising potential in treating relapsed/refractory ALL, attracting the attention of researchers.
FRONTIERS IN ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Benjamin Micallef, Robert Nistico, Sinan B. Sarac, Ole W. Bjerrum, Dianne Butler, Nicolette Sammut Bartolo, Anthony Serracino-Inglott, John Joseph Borg
Summary: New treatments for paediatric acute lymphoblastic leukaemia (ALL) are being developed, but bridging the gap between bench science and clinical application remains challenging. Current research focuses on multidrug chemotherapy with the potential addition of new targeted molecules for first-line treatment, and precision medicine through innovative and immuno-oncology products for second- and third-line treatment. Collaborative research involving different stakeholders should be intensified to facilitate the translation of scientific research into clinical practice for the benefit of patients.
DRUG DISCOVERY TODAY
(2022)
Article
Medicine, General & Internal
J. Feng, Frankie W. T. Cheng, Alan K. S. Chiang, Grace K. S. Lam, Terry T. W. Chow, S. Y. Ha, C. W. Luk, C. H. Li, S. C. Ling, P. W. Yau, Karin K. H. Ho, Alex W. K. Leung, Natalie P. H. Chan, Margaret H. L. Ng, C. K. Li
Summary: Compared with young children with acute lymphoblastic leukaemia (ALL), adolescents with ALL have less favourable genetic features and poorer response to initial treatment, leading to lower survival rates primarily due to a higher incidence of treatment-related death (TRD).
HONG KONG MEDICAL JOURNAL
(2022)
Review
Genetics & Heredity
Elena-Silvia Shelby, Michael Morris, Liliana Padure, Andrada Mirea, Relu Cocos, Alexandru Caramizaru, Simona Serban-Sosoi, Andrei Pirvu, Ioana Streata
Summary: 19q13 microdeletion syndrome is a rare genetic disease characterized by growth retardation and intellectual disability. This article reports the first case of this syndrome in Romania, with some unique features not previously reported.
Review
Biochemistry & Molecular Biology
Abdul Mannan, Zacary P. Germon, Janis Chamberlain, Jonathan R. Sillar, Brett Nixon, Matthew D. Dun
Summary: Acute lymphoblastic leukaemia (ALL) is the most common cancer in children and adolescents, with elevated reactive oxygen species (ROS) playing a significant role in disease progression and chemotherapy resistance. Therapeutic strategies targeting ROS production, especially focusing on enzymes like NADPH oxidases (NOXs), may present alternative approaches to improve the treatment of ALL.
Review
Pharmacology & Pharmacy
Zhaoying Chen, Qianling Xin, Wei Wei, Yujing Wu
Summary: Acute lymphoblastic leukaemia (ALL) is divided into acute T- and B-lymphoblastic leukaemia based on the source of lymphocytes. Adult T-cell ALL accounts for about 25% of adult ALL, but has poor prognosis and limited treatment options. Understanding the pathogenesis of T-ALL is crucial for developing new targeted drugs. Dysregulated signalling pathways play a key role in promoting tumour progression and are potential targets for novel therapeutic agents.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Genetics & Heredity
Josef Davidsson, Anna Collin, Gudrun Bjorkhem, Maria Soller
BMC MEDICAL GENETICS
(2008)
Article
Hematology
Kristina Karrman, Eigil Kjeldsen, Carin Lassen, Margareth Isaksson, Josef Davidsson, Anna Andersson, Henrik Hasle, Thoas Fioretos, Bertil Johansson
BRITISH JOURNAL OF HAEMATOLOGY
(2009)
Article
Clinical Neurology
Josef Davidsson, Anna Collin, Mia Engman Olsson, Johan Lundgren, Maria Soller
Article
Biochemistry & Molecular Biology
Josef Davidsson, Henrik Lilljebjorn, Anna Andersson, Srinivas Veerla, Jesper Heldrup, Mikael Behrendtz, Thoas Fioretos, Bertil Johansson
HUMAN MOLECULAR GENETICS
(2009)
Letter
Oncology
J. Davidsson, H. Lilljebjorn, I. Panagopoulos, T. Fioretos, B. Johansson
Article
Oncology
J. Davidsson, K. Paulsson, D. Lindgren, H. Lilljebjorn, T. Chaplin, E. Forestier, M. K. Andersen, A. Nordgren, R. Rosenquist, T. Fioretos, B. D. Young, B. Johansson
Article
Endocrinology & Metabolism
Josef Davidsson, Karen Jahnke, Maria Forsgren, Anna Collin, Maria Soller
Article
Genetics & Heredity
Josef Davidsson, Srinivas Veerla, Bertil Johansson
EPIGENETICS & CHROMATIN
(2013)
Article
Biochemistry & Molecular Biology
Josef Davidsson, Anna Andersson, Kajsa Paulsson, Markus Heidenblad, Margareth Isaksson, Ake Borg, Jesper Heldrup, Mikael Behrendtz, Ioannis Panagopoulos, Thoas Fioretos, Bertil Johansson
HUMAN MOLECULAR GENETICS
(2007)
Letter
Hematology
J Davidsson, K Paulsson, B Johansson
EUROPEAN JOURNAL OF HAEMATOLOGY
(2006)
Article
Oncology
J Davidsson, K Paulsson, B Johansson
CANCER GENETICS AND CYTOGENETICS
(2005)
Article
Genetics & Heredity
J. Davidsson, A. Collin, M. Oereberg, D. Gisselsson
Letter
Oncology
Josef Davidsson, Markus Heidenblad, Ake Borg, Bertil Johansson
CANCER GENETICS AND CYTOGENETICS
(2006)
